TELA Bio

1 Great Valley Parkway
Suite 24
Malvern
Pennsylvania
19355
United States

Tel: 484-320-2930

Email: info@telabio.com

Show jobs for this employer

About TELA Bio

TELA Bio, Inc. is a privately-owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients.

YEAR FOUNDED:

2012

LEADERSHIP:

Founders: Antony Koblish and Maarten Persenaire

Founder and CEO: Antony Koblish

Founder and CMO: Maarten Persenaire

CTO: Skott Greenhalgh

PRODUCTS:

All Products

 

54 articles with TELA Bio

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2020. Preliminary Unaudited Fourth Quarter and Full Year Results: Fourth quarter revenue is expec

  • TELA Bio, Inc., an innovative MedTech company focused on advancing the field of soft-tissue reconstruction, announced that it has welcomed Bruce Freedman, M.D., FACS as Vice President of Clinical Development.

  • TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday, December 3, 2020. A link to the fireside chat prese

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the third quarter ended September 30, 2020. 

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company plans to participate in two upcoming investor conferences.

  • TELA Bio, Inc. announced that it will be featured on The Balancing Act to increase patient awareness of mesh options for hernia repair, including its next-generation soft-tissue repair solution, OviTex.

  • TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 third quarter financial results on November 11, 2020.

  • TELA Bio, Inc. announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company plans to participate in two upcoming conferences.

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020.  Recent Highlights Reported revenue of $3.5 million for the second quarter of 2020, increasing 6% over the second quarter of 2019  

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announces it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020.

  • TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 second quarter financial results on August 12, 2020. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial r

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the results of an interim analysis from the company's post-market BRAVO study evaluating the clinical performance of OviTex for the treatment of ventral hernias.

  • TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the closing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share,

  • TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share for gross proceeds of $48.0 million, before underwriting discounts and commiss

  • TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the commencement of a proposed underwritten public offering of 3,000,000 shares of its common stock.  

  • TELA Bio, Inc. announced that the company will be added to the Russell 2000® Index at the conclusion of the Russell U.S. Indices annual reconstitution, effective after the U.S. market opens on June 26, 2020.

  • TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that two abstracts focused on evaluating OviTex® products have been accepted for poster presentations at the 20th annual Minimally Invasive Surgery Symposium.

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference. TELA Bio's management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (E

  • TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2020.